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Gefitinib versus chemotherapy as first-line treatment in elder 
patients with advanced non-small-cell lung cancer 
Zhang, Xiao-Tong; Li, Long-Yun; Wang, Men-Zhao; Zhang, Li;  
Zhong, Wei
Peking Uion Medical College Hospital & Chinese Academy of Medical 
Sciences, Beijing, China
Background: Elder patients with non-small cell lung cancer (NSCLC) 
have been habitually underrepresented in clinical trails. Retrospective 
analysis have shown similar therapeutic outcome of platinum-based 
combined chemotherapy for ﬁt elderly, albeit more toxicity compared 
with younger counterparts. Geﬁtinib, an oral EGFR-TKI was generally 
well tolerated with clinically meaningful anti-tumor activity in previ-
ously treated patients as well as chemo-na&iuml;ve patients. The aim 
of the study was to retrospectively evaluate the toxicity, efﬁcacy and 
survival of geﬁtinib versus platinum-based combined chemotherapy 
as ﬁrst-line treatment for a series of Chinese patients aged 70 and over 
with advanced NSCLC. 
Methods: from January 2002 to December 2005, 38 patients received 
chemotherapy (17 of Novelbine, 8 of Gemcitabine, 7 of taxol and 7 of 
taxotere, all of which combined with cisplatin or carboplatin) and 17 
patients received geﬁtinib 250mg once daily as ﬁrst line treatment. 
Results: Of the 38 patients who received chemotherapy, the median 
age was 73.3 years old (70-80) with 68.4% male, 73.7% adenocar-
cinoma and 78.9% patients were in stage 4. The PS of all patients 
was 0-1. Of the 17 patients who received geﬁtinib, the median age 
was 76.9 years old (70-85) with 58.8% male, 64.7% adenocarcinoma 
and 82.4% patients were in stage 4. The PS of 6 patients was over 2. 
The most frequently reported adverse events for chemotherapy group 
were neutropenia (92.1%) and thrombocytopenia(73.7%). Grade 3/4 
neutropenia was 21.1% and four patients had nertropenia febril. Grade 
3/4 thrombocytopenia was 10.5% and 2 patients need blood transfu-
sion. Other grade 3/4 adverse effects included 3 cases of vomiting and 
one case of cardiac arrhythmia. 4 patients withdrew the chemotherapy 
due to side effects. The most frequently reported adverse events for 
geﬁtinib group were skin disorders (70.6%) and diarrhea (35.3%). The 
majority of these events were mild with grade 1 to grade 2. One patient 
was hospitalization due to grade 3 diarrhea and recovered without drug 
administration disruption. Other adverse events included 2 cases of 
nausea, 1 case of oral ulcer and 1 case of elevation in hepatic enzymes. 
No patient withdrew due to adverse effect. The partial response and 
disease control rate were 21.1% and 78.9% for chemotherapy group 
versus 17.6% and 68.8% for geﬁtinib group. The median progress free 
survival and overall survival time were 4.93 ± 0.747 months (95% CI: 
3.465, 7.395) and 13.882 ± 0.718 months (95% CI: 12.892, 20.708) 
for chemotherapy group versus 6.4 ± 1.852 months (95%CI: 2.770, 
10.030) and 15.882 ± 2.029 months (95%CI: 13.654, 20.505). The one-
year survival was 52.6% in chemotherapy group versus 47.1% in geﬁ-
tinib group. There is no statistical signiﬁcance between the two groups 
for efﬁcacy, progress free survival time and overall survival time. 
Conclusion: Platinum-based combined chemotherapy was well toler-
ated and provides signiﬁcant anti-tumor activity in elder patients. 
Geﬁtinib as ﬁrst-line treatment provides similar clinical beneﬁt with 
less toxicity for the elder NSCLC patients. 
P3-164 NSCLC: Molecular Targeted Therapy Posters, Wed, Sept 5 – Thurs, Sept 6 
A phase II trial of pemetrexed(p) in patients (pts) with performance 
status (PS) 2 and 3 as 1st- and 2nd- line treatment for advanced 
non-small-cell lung cancer (NSCLC)
Zinner, Ralph G. Fossella, Frank V. Kies, Merrill Herbst, Roy S. Lu, 
Charles Johnson, Faye Price, Justina Cleeland, Charles Wang, Shirley 
UT MD Anderson Cancer Center, Houston, TX, USA
P (Alimta) is approved as 2nd-line therapy in pts with advanced 
NSCLC. In a phase III trial comparing P with docetaxel (D), median 
survival was 8.3 mos (P) vs 7.9 mos (D); P had a more favorable safety 
proﬁle than D (Hanna, 2004). There are few data on pts with PS 3, and 
ASCO 2003 guidelines recommend that chemotherapy be reserved for 
pts with PS 0, 1 and possibly 2. Since P is well tolerated, PS3 pts may 
tolerate and beneﬁt from it. In this trial, we treated 20 pts with stage 
IIIb/IV NSCLC and PS 2 or 3, who were chemo-naive or had received 
1 prior regimen. Pts received P 500mg/m2 IV D1 Q 3 wks. All pts 
received folic acid, vitamin B12 and dexamethasone prophylaxis. Serial 
blood samples were obtained to monitor inﬂammatory cytokines, and 
symptoms were monitored using the validated MDASI instrument. All 
pts were assessable for toxicity-symptoms, and 17 pts were evaluable 
for response (assessed after 1st cycle). Pt characteristics: 8 pts were PS 
3 (4/8 1st line) and 12 pts were PS 2 (6/12 1st line). Median age was 
69 for PS3 and 68 for PS2. 5/8 PS3 pts and 6/12 PS2 pts were men. 
2/8 PS3 pts and 4/12 PS2 pts had stage IIIb. 4/8 PS3 pts and 6/12 PS2 
pts were chemo-naïve. Grade 3-4 toxicities for PS3/PS2 cohorts were: 
neutropenia 0/1 pt, anemia 1/2, fatigue 2/0, pneumonia 1/1, hypoten-
sion 1/1, neutropenic fever 0/1, atrial ﬁbrillation 1/1. Response rates 
(RR) in PS3 pts were minor response (MR) 1/8, stable disease (SD) 
5/8, progressive disease (PD) 2/8; RR in PS2 pts were partial response 
(PR) 1/12, MR 2/12, SD 3/12, PD 3/12, inevaluable 3/12. RR by line 
of therapy: 1st line 6/10 SD, 2/10 PD, 2/10 inevaluable, and 2nd line, 
1/10 PR, 2/10 MR, 3/10 SD, 3/10 PD, and 1/10 inevaluable. Reasons 
for PS3 pts coming off study were progression (4/8), constitutional 
toxicity (3/8), fatal pulmonary emboli (1/8); PS2 pts came off study 
due to progression (5/12), constitutional toxicity (2/12), and pneumonia 
(1/12). 4/12 PS2 pts are still on study. These preliminary data suggest 
that single-agent P is well-tolerated and has a promising RR in poor PS 
pts. Total planned accrual is 30 PS3 and 45 PS2 pts. Survival, symp-
tom, and cytokine data will be presented.
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Utility of SPECT for metabolic and functional lung imaging in 
radiation therapy treatment planning for lung cancer
Agrawal, Sushma; Kheruka, Subhash; Das, Maria; Raj, Karthik; Lal, 
Punita; Gambhir, Sanjay 
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, 
India
Background: Conformal radiotherapy of lung tumors relies on ana-
tomic imaging with CT scan to deﬁne both targets and critical structures, 
but has its drawbacks in differentiating atelectasis from tumor. Also, it 
may not represent the metabolic tumor volume and functional lung vol-
ume. We attempted to evaluate the utility of SPECT to gain information 
